Unum Therapeutics Announces Transition of Chief Financial Officer
“I want to thank Christiana for her tireless efforts over the last four years as we have worked to build a leading publicly-traded, clinical-stage cell therapy company with a broad and growing pipeline,” said Dr. Wilson. “Christiana has played a pivotal role in supporting our growth, and we wish her the best as she explores the next chapter in her career.”
“I am fortunate to have worked at such a remarkable organization and to have been a part of Unum’s transformation from a very early-stage startup into a fast-growing public company in the high-potential field of cancer cell therapy,” said Ms. Stamoulis. “With its exceptional team, promising emerging data, and rich clinical pipeline of products,
Forward looking Statements
This press release contains forward-looking statements. Statements in this press release about our future expectations, plans and prospects, including statements regarding the changes in our officer positions, the Company’s plan to appoint a new Chief Financial Officer, the anticipated timing of our clinical trials and regulatory filings, our long-term growth and our ability to achieve our strategy, the development of our product candidates, including the three lead ACTR product candidates, the results of our clinical trials, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to the accuracy of our estimates regarding expenses, future revenues, capital requirements, and the need for additional financing, the success, cost and timing of our product development activities and clinical trials, our ability to obtain and maintain regulatory approval for our product candidates, and the other risks and uncertainties described in the "Risk Factors" sections of our public filings with the
Source: Unum Therapeutics Inc.